Isomorphic Labs secured a $2.1 billion Series B round to scale its AI predictive drug discovery engine and advance its internal pipeline toward the clinic. Reports describe a syndicate led by Thrive Capital, with new and existing investors participating, marking one of the largest biotech venture financings ever. The company said the funding will support continued development of its computational drug-design system (IsoDDE) and scale hiring across AI, engineering, drug design, and clinical development, while it expands beyond early prototypes toward broader therapeutic execution.